These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26393386)

  • 1. Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial.
    Li ZJ; Wu Q; Yi CJ
    Curr Med Res Opin; 2015 Nov; 31(11):2055-8. PubMed ID: 26393386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
    Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive transcranial magnetic stimulation of the primary motor cortex in the treatment of motor signs in Parkinson's disease: A quantitative review of the literature.
    Zanjani A; Zakzanis KK; Daskalakis ZJ; Chen R
    Mov Disord; 2015 May; 30(6):750-8. PubMed ID: 25786995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease.
    Shin HW; Youn YC; Chung SJ; Sohn YH
    J Neurol; 2016 Jul; 263(7):1442-8. PubMed ID: 27178002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of 1 Hz Inhibitory and 5 Hz Excitatory Repetitive Transcranial Magnetic Stimulations in Parkinson's Disease: A Functional Magnetic Resonance Imaging Study.
    Bhat P; Goyal V; Kumaran SS; Srivastava AK; Behari M; Dwivedi SN
    Brain Connect; 2023 May; 13(4):247-263. PubMed ID: 36869613
    [No Abstract]   [Full Text] [Related]  

  • 10. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
    Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
    Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study.
    Shirota Y; Ohtsu H; Hamada M; Enomoto H; Ugawa Y;
    Neurology; 2013 Apr; 80(15):1400-5. PubMed ID: 23516319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
    Shimo Y; Maeda T; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Watanabe H; Saiki H;
    Parkinsonism Relat Disord; 2021 Oct; 91():115-120. PubMed ID: 34583302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson's disease.
    Maruo T; Hosomi K; Shimokawa T; Kishima H; Oshino S; Morris S; Kageyama Y; Yokoe M; Yoshimine T; Saitoh Y
    Brain Stimul; 2013 Nov; 6(6):884-91. PubMed ID: 23769414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.
    Sayın S; Cakmur R; Yener GG; Yaka E; Uğurel B; Uzunel F
    J Clin Neurosci; 2014 Aug; 21(8):1373-6. PubMed ID: 24631324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.
    Bäumer T; Hidding U; Hamel W; Buhmann C; Moll CK; Gerloff C; Orth M; Siebner HR; Münchau A
    Mov Disord; 2009 Apr; 24(5):672-6. PubMed ID: 19185021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.